Senores Pharma Allots 11.7 Lakh Warrants Worth ₹95 Cr on Preferential Basis
Senores Pharmaceuticals approved the allotment of 11.7 lakh warrants convertible into equity shares. The total issue size is ₹95.004 Crore, with ₹23.751 Crore received upfront. The exercise price is ₹812 per warrant, and conversion is expected within 18 months.
The preferential issue of warrants represents a significant capital raise, which can impact the company's financial structure and potentially lead to dilution for existing shareholders upon conversion. The amount raised is substantial relative to the company's size.
The company is raising capital through preferential allotment of warrants, which is generally viewed positively as it can fund growth or operational expansion.
Senores Pharmaceuticals Limited announced the outcome of its Board Meeting held on March 28, 2026, where it approved the allotment of 11,70,000 warrants convertible into equity shares. These warrants are issued on a preferential basis at an exercise price of ₹812 per warrant, aggregating to ₹95,00,40,000 (₹95.004 Crore).
An upfront payment of ₹203 per warrant, totaling ₹23,75,10,000 (₹23.751 Crore), has been received as the warrant subscription price. The allotment follows earlier approvals from the company's members on January 31, 2026, and in-principle approvals from BSE and NSE on March 13, 2026. The warrants are subject to lock-in restrictions as per SEBI ICDR Regulations.
The Board meeting commenced at 11:45 A.M. (IST) and concluded at 12:07 P.M. (IST). The warrants can be exercised within a maximum period of 18 months from the allotment date, with the balance payment of ₹609 per warrant due upon exercise. The total post-issue shareholding of the five allottees, assuming full conversion, will increase to 25.26% of the company's equity.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under equity fundraising. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.